General Information of the Drug (ID: M6APDG03625)
Name
NMS-1
Status
Investigative
TTD Drug ID
D03BQD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Polo-like kinase 1 (PLK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Polo-like kinase 1 (PLK1) is a therapeutic target for NMS-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NMS-1 through regulating the expression of Polo-like kinase 1 (PLK1). [1], [2]
References
Ref 1 METTL3-mediated m(6)A modification regulates cell cycle progression of dental pulp stem cells. Stem Cell Res Ther. 2021 Mar 1;12(1):159. doi: 10.1186/s13287-021-02223-x.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).